David J Rog

Summary

Country: UK

Publications

  1. ncbi request reprint Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
    David J Rog
    Walton Centre for Neurology and Neurosurgery, University of Liverpool, Liverpool, United Kingdom
    Neurology 65:812-9. 2005
  2. ncbi request reprint Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosis
    David J Rog
    Walton Centre for Neurology and Neurosurgery, Liverpool, UK
    Clin J Pain 23:473-81. 2007
  3. ncbi request reprint Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
    David J Rog
    Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom
    Clin Ther 29:2068-79. 2007

Detail Information

Publications3

  1. ncbi request reprint Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
    David J Rog
    Walton Centre for Neurology and Neurosurgery, University of Liverpool, Liverpool, United Kingdom
    Neurology 65:812-9. 2005
    ..Central pain in multiple sclerosis (MS) is common and often refractory to treatment...
  2. ncbi request reprint Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosis
    David J Rog
    Walton Centre for Neurology and Neurosurgery, Liverpool, UK
    Clin J Pain 23:473-81. 2007
    ..The Neuropathic Pain Scale (NPS) has received preliminary validation in peripheral neuropathic pain conditions. The aim of this study was to validate its use in MS central pain syndromes...
  3. ncbi request reprint Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
    David J Rog
    Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom
    Clin Ther 29:2068-79. 2007
    ..Delta(9)-Tetrahydrocannabinol/cannabidiol (THC/CBD), an endocannabinoid system modulator, has demonstrated efficacy for up to 4 weeks in randomized controlled trials in the treatment of CNP in patients with MS...